Improved quality of life with fremanezumab in Japanese and Korean patients with episodic and chronic migraine: Results of two multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group clinical trials

Abstract

AbstractObjectiveTo evaluate quality of life (QoL) endpoints from two 12‐week trials investigating fremanezumab efficacy and safety in Japanese/Korean patients with chronic (CM) or episodic (EM) migraine.BackgroundMigraine is a leading cause of disability and affects QoL considerably, interfering with work and daily activities, social and family life, and emotional wellbeing.MethodsThis planned exploratory analysis used data from two multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group studies in which Migraine‐Specific QoL (MSQoL; Role Function‐Restrictive [RR], Role Function‐Preventive [RP], and Emotional Function [EF] domains) scores and Patient Global Impression of Change (PGIC) scores were pre‐specified QoL outcomes in individuals receiving monthly or quarterly fremanezumab or placebo. In both trials, MSQoL was assessed at baseline, and MSQoL and PGIC at Weeks 4, 8, and 12. PGIC responders had a score of ≥5 points, indicating significant improvement.ResultsMean baseline MSQoL scores were similar across groups in both CM (N = 565; RR, 60.3–61.5; RP, 78.5–80.0; EF, 69.0–71.4) and EM (N = 353; RR, 68.6–71.1; RP, 83.1–85.7; EF, 76.7–81.9) trials. In the CM trial, all three MSQoL domains improved in both fremanezumab groups at 12 weeks compared with placebo: least squares mean (LSM) and standard error (SE) change from baseline,pversus placebo (quarterly; monthly; placebo): RR 14.9 (1.3),p = 0.030; 15.1 (1.4),p = 0.020; 11.6 (1.3); RP 8.9 (1.1),p = 0.007; 8.6 (1.1),p = 0.013; 5.4 (1.1); EF 13.3 (1.5),p < 0.001; 12.5 (1.5),p = 0.003; 7.5 (1.5). In the EM trial, RR/EF domains improved in both fremanezumab groups compared with placebo: LSM change from baseline,pversus placebo (quarterly; monthly; placebo): RR 16.3 (1.4),p = 0.003; 16.4 (1.3),p = 0.002; 11.6 (1.4); EF 13.0 (1.3),p < 0.001; 11.5 (1.2),p = 0.004; 7.4 (1.3); RP improved in the quarterly group RP 8.6 (1.1),p = 0.010; 7.6 (1.1),p = 0.066; 5.4 (1.1). The proportion of PGIC responders at Week 12 was greater in the monthly and quarterly fremanezumab groups compared with the placebo group in the CM (96/182 [52.7%] and 98/180 [54.4%] vs. 68/179 [38.0%];p < 0.05) and EM trial (81/118 [68.6%] and 86/113 [76.1%] vs. 38/111 [34.2%];p < 0.001).ConclusionPatients with EM/CM receiving monthly or quarterly fremanezumab, for a duration of 12 weeks, showed significant improvements in their QoL.